Alopecia

Platelet-rich plasma (PRP) is an autologous serum containing high concentrations of platelets and growth factors. PRP continues to evolve as an important treatment modality with many applications in dermatology, particularly in the areas of hair restoration, skin rejuvenation, acne scars, dermal augmentation, and striae distensae.

Frontal fibrosing alopecia has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. It has distinctive features and associations which distinguish it from LPP. Discussion includes familial or genetic factors, etiology, and trials.

This update summarizes current concepts, relevance, and therapeutics in psychodermatology, including aspects pertinent to depression, anxiety, obsessive-compulsive, impulse-control, and delusional disorders as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. This article review recent Phase III clinical trials on Minoxidil efficacy for the treatment of female patter hair loss.

Autoimmune blistering diseases are rare, but potentially debilitating characterized by varying degrees of mucosal and cutaneous bullae formation. This article discusses individually tailored treatment, diagnosis, severity, comorbidities, and tolerance for systemic therapy.

Hair loss is a common dermatological problem that affects a large segment of the population both physically and psychologically. Currently, only one topical agent is approved for treatment of hair loss in men, although other treatments are being clinically investigated.

Hair loss is a widespread complaint that carries a significant psychosocial burden for affected individuals. Androgenetic alopecia (AGA) is the predominant cause of hair loss seen in the dermatology clinic. This article reviews a range of therapies that are available for AGA treatment.

Hair loss is a common dermatological problem that affects a large segment of the population both physically and psychologically. This article focuses on androgenetic alopecia (AGA) or male pattern hair loss, as well as the common treatments, Minoxidil and other topical treatments.

Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. Here we briefly review current therapeutic options and treatments under active investigation.

Chemotherapy-induced hair loss occurs with an estimated incidence of 65%. This article discusses hair loss, topical minoxidil, scalp cooling and chemotherapy induced hair loss.

As hair transplant surgery has evolved, combinations of micrografting and minigrafting have enabled physicians to produce ever more natural combinations of both. A wide range of men and women can now receive significant aesthetic benefits from hair transplants.

Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety.

Finasteride 1 mg (Propecia®, Merck) was approved by the US FDA December, 1997 for the treatment of male pattern hair loss (androgenetic alopecia, AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior mid-scalp area.

Androgenetic alopecia is a stressful experience for both sexes, but possibly more distressing for women. An overview of the condition, treatments, and considerations surrounding alopecia.